

□□□□□ □□□ :

إِذَا مَرَضْتُ فَهُوَ يَشْفِينِ {80} وَالَّذِي يُمِيتُنِي
ثُمَّ يُحْيِينِ {81} وَالَّذِي أَطْمَعُ أَنْ يَغْفِرَ لِي
خَطِيئَتِي يَوْمَ الدِّينِ {82}

□ □ □ □ □ □ □ □ □ □ □ □ □

00 -00) 000000 - 000000 0000)

DEDICATION

To ...

*Our dear fathers
Our dear mother*

*Who made my life simple
and warm; they
are great, and nothing
great without them.*

*Our sisters
Our brothers
Our dear friends
Our teachers*

To

Heart disease patients

Acknowledgements

All my thanks are in the name of Allah, the most Gracious and the most Merciful.

I would like to express my profound thanks to my supervisor, Dr. Abd - Gadir Ali Elmugadam for his fruitful guidance, unlimited assistance, encouragement and sustained interest throughout the course of this work.

I wish to extend my warmest thanks to the staff of the Clinical Chemistry Department, Sudan University of Science and Technology, for their continuous support and encouragement.

My thanks are also extended to Ahmed Mohamed, Magzob, Mohamed Alamin, and Emtinan Elamin for help me.

Also I am grateful to all people from whom samples were taken.

Abstract

An analytical case control study conducted during the period from January to July 2011, compared serum levels of total cholesterol, triglycerides, high density lipoproteins and low density lipoproteins of 30 acute myocardial infarction patients (as test group), 30 health subject (as control group), and 30 admitted individual with no AMI (as base control). Participants in this study were from Alshab hospital.

The serum levels of triglycerides, total cholesterol, high density lipoproteins and low density lipoproteins were measured using A25 Bio System Chemistry analyzer and commercial kits from Bio System Company.

The mean of the serum levels of triglycerides of the test group was significantly increased when compared to control group , ($P= 0.003$), while there was no significant difference when compared to base control , ($P= 0.186$).

The mean of the serum levels of total cholesterol, high density lipoproteins, and low density lipoproteins of the test group showed no significant difference when compared to control group, ($p=0.473$), ($P= 0.056$), ($P=0.856$) and base control, ($p= 0.061$), ($P= 0.273$), ($P= 0.177$).

In the AMI (test group) the serum levels of triglyceride showed no correlation with age $P.value < 0.05$ Whereas the serum levels of total cholesterol and low density lipoproteins showed a weak positive correlation $P.value < 0.05$. The serum levels of high density lipoproteins showed no correlation with age $P.value < 0.05$.

From the results of this study, it is concluded that there are no difference in serum levels of total cholesterol, low density lipoproteins and high density lipoproteins and significant increase in triglyceride.

00000000 00000000 000 00000000 000000 00000 00000 00 0000000 00000 00000000000000000000 000 000000
 00 0000000 00000000000 0000000000 000000000 00 0000000 000000000000 000000000000 000000000 00000000
 00000000) 0000000 000000000 000000000 00000000000 00000000 00 **30** 000 0000000000 00000000
 (0000000000 0000

[illegible][illegible][illegible]

在 2019 年 12 月 31 日，本集团持有的金融资产和负债的公允价值如下：

金融资产和负债	公允价值
货币资金	1,000,000,000
应收账款	500,000,000
其他应收款	200,000,000
长期股权投资	1,500,000,000
固定资产	800,000,000
无形资产	300,000,000
其他非流动资产	100,000,000
应付账款	400,000,000
其他应付款	250,000,000
长期借款	1,200,000,000
应付债券	600,000,000
其他金融负债	150,000,000

公允价值计量的层次性：

金融资产和负债	公允价值	公允价值计量的层次性
货币资金	1,000,000,000	第一层次
应收账款	500,000,000	第二层次
其他应收款	200,000,000	第二层次
长期股权投资	1,500,000,000	第三层次
固定资产	800,000,000	第三层次
无形资产	300,000,000	第三层次
其他非流动资产	100,000,000	第三层次
应付账款	400,000,000	第二层次
其他应付款	250,000,000	第二层次
长期借款	1,200,000,000	第二层次
应付债券	600,000,000	第二层次
其他金融负债	150,000,000	第二层次

公允价值计量的方法：

金融资产和负债	公允价值计量的方法
货币资金	账面价值
应收账款	未来现金流量折现
其他应收款	未来现金流量折现
长期股权投资	市场法
固定资产	重置成本法
无形资产	收益法
其他非流动资产	重置成本法
应付账款	未来现金流量折现
其他应付款	未来现金流量折现
长期借款	未来现金流量折现
应付债券	未来现金流量折现
其他金融负债	未来现金流量折现

公允价值计量的假设：

金融资产和负债	公允价值计量的假设
货币资金	假设货币资金在资产负债表日不存在减值
应收账款	假设应收账款在资产负债表日不存在减值
其他应收款	假设其他应收款在资产负债表日不存在减值
长期股权投资	假设长期股权投资在资产负债表日不存在减值
固定资产	假设固定资产在资产负债表日不存在减值
无形资产	假设无形资产在资产负债表日不存在减值
其他非流动资产	假设其他非流动资产在资产负债表日不存在减值
应付账款	假设应付账款在资产负债表日不存在减值
其他应付款	假设其他应付款在资产负债表日不存在减值
长期借款	假设长期借款在资产负债表日不存在减值
应付债券	假设应付债券在资产负债表日不存在减值
其他金融负债	假设其他金融负债在资产负债表日不存在减值

公允价值计量的披露：

金融资产和负债	公允价值计量的披露
货币资金	在资产负债表中披露
应收账款	在资产负债表中披露
其他应收款	在资产负债表中披露
长期股权投资	在资产负债表中披露
固定资产	在资产负债表中披露
无形资产	在资产负债表中披露
其他非流动资产	在资产负债表中披露
应付账款	在资产负债表中披露
其他应付款	在资产负债表中披露
长期借款	在资产负债表中披露
应付债券	在资产负债表中披露
其他金融负债	在资产负债表中披露

[illegible]

CONTENTS

TOPIC	PAGE
□□□□□	
Dedication	I
Acknowledgements	II
Abstract	III
□□□□□□□ □□□□	IV
Contents	V
Abbreviations	VI
List of tables	IX
List of figures	X
CHAPTER ONE	
	Introduction, Rational, and Objectives
1.1.	Introduction
1.2.	Rational
1.3.	Objectives
CHAPTER TWO	
	Literature Review
2.1.	Heart
2.1.1.	Normal Functionand Structure
2.1.2.	Cardiac cycle
2.1.3.	Cardiac Failure
2.1.4.	Ischemic Heart Disease
2.1.5.	Acute Myocardial Infarction
2.1.5.1.	Clinical Feature
2.1.5.2.	Morphology of the patient
2.1.5.3.	Complication of AMI
2.1.5.4.	Diagnosis
2.1.5.5.	Treatment
2.2.	Lipids
2.3.	Apo lipoproteins
2.4.	Lipoproteins
2.4.1.	Classification of lipoproteins
2.4.2.	Lipoprotein metabolism
2.4.3.	Lipoprotein receptor
2.4.4.	Effect of hormones on lipoproteins

2.5.	Disorders of lipid metabolism	37
2.6.	Treatment of Hyperlipidaemia	43
CHAPTER THREE		
	Materials and Methods	
3.1.	Study approach	44
3.2.	Study design	44
3.3.	Study area	44
3.4.	Study period	44
3.5.	Study population and sample size	44
3.6.	Criteria for selection of cases	44
3.6.1.	Test group	44
3.6.2.	Control group	44
3.7.	Ethical consideration	45
3.8.	Data collection and analysis	45
3.8.1.	Interview and Questionnaire	45
3.9.	Collection of blood sample	45
3.10.	Methodology	46
3.11.1.	Measurement of serum cholesterol	46
3.11.2.	Measurement of triglyceride	47
3.11.3.	Measurement of HDL-C	47
3.11.4.	Measurement of LDL-C	48
3.16.	Quality control	49
3.17.	Statistical analysis	49
CHAPTER FOUR		
4.	Results	50
CHAPTER FIVE		
	Discussion, Conclusion and Recommendation	
5.1.	Discussion	62
5.2	Conclusion	64
5.3	Recommendation	65
	References	66
	Appendices	

Abbreviations

AMI : Acute myocardial infarction.
AV : a trio-ventricular.
ATP : adenosine tri phosphate.
AST : Aspartate Aminotransferase.
CHD : Coronary heart disease.
CK : Creatine kinase.
CABG: Coronary artery bypass graft.
C-H : carbon –hydrogen.
CETP : cholesteryl ester transferase protein.
ECG : Electrocardiography.
FFAs : Free Fatty Acids.
HDL : High density lipoprotein.
IHD : Ischemic heart disease.
IDL : Intermediate density lipoprotein.
LDH : Lactate dehydrogenase.
LDL : Low density lipoproteins.
LPL : lipoprotein lipase.
LCAT: lecithin–cholesterolacyltransferase.
PTCA: Percutaneous transluminal coronary angioplasty.
SA : sino atrial.
TnT : Troponin-T.
TnI : Troponin-I.
TnC : Troponin-C.
VLDL: Very low density lipoproteins.
WHO : World Health Organization.

List of tables

Table number	Title	Page NO
Table (2-1)	Adult reference range for serum lipids	19
Table (2-2)	Characteristic of human apolipoproteins	24
Table (2-3)	Characteristic of human lipoproteins	28
Table (2-4)	Enzymes of plasma lipoprotein metabolism	30
Table (4-1)	Serum lipid profile in base control group compared to control group.	55
Table (4-2)	Serum lipid profile in base control group compared to test group.	56
Table (4-3)	Serum lipid profile in test group compared to Control group	57

List of Figures

Figures NO	Title	Page NO
Figure (4-1)	Show frequency of sex in the patient with AMI (test group)	52
Figure (4-2)	Show frequency of sex in the control& base control group	53
Figure (4-3)	Show frequency of age group in the three groups	54
Figure (4-4)	Correlation of age and serum cholesterol in test group.	58
Figure (4-5)	Correlation of age and serum triglyceride in test group.	59
Figure (4-6)	Correlation of age and serum LDL- cholesterol in test group.	60
Figure (4-7)	Correlation of age and serum HDL- cholesterol in test group.	61